ReviewWorld journal of gastroenterology2013
Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management.
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.The Lancet. Haematology · 2024Trial
- Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.Medicine · 2017Trial
- Article
- Clinical characteristics and long-term prognosis of primary mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma in the small intestine.Translational cancer research · 2025Article
- Concurrent esophageal squamous cell carcinoma with gastric mucosa-associated lymphoid tissue lymphoma: a case report.Frontiers in oncology · 2025Article
- Transformed gastric mucosa-associated lymphoid tissue lymphoma originating in the colon and developing metachronously afterWorld journal of gastrointestinal oncology · 2024Article
- Endoscopic Features of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma withoutDiagnostics (Basel, Switzerland) · 2024Article
- Efficacy and Mechanism of Core Traditional Chinese Medicines for Treating Malignant Lymphoma based on Efficacy Studies: A Study Supported by Network Pharmacology and Molecular Docking.Current pharmaceutical design · 2024Article
- Effects and mechanisms ofFrontiers in immunology · 2024Review
- Role of non-World journal of gastroenterology · 2023Review
- The Anti-Cancer Effect of Cinnamon Aqueous Extract: A Focus on Hematological Malignancies.Life (Basel, Switzerland) · 2023Review
- Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model.The Journal of pathology · 2023Article
- Misdiagnosis analysis of 2291 cases of haematolymphoid neoplasms.Frontiers in oncology · 2023Article
- Article
- Article
- Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.Journal of clinical medicine · 2022Review
- Multimodality imaging findings of infection-induced tumors.Abdominal radiology (New York) · 2022Review
- Child With Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue.JPGN reports · 2021Article
- Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease pathogenesis and treatment.World journal of gastroenterology · 2021Review
- Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in the research regarding the molecular pathogenesis and management of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is reviewed. In approximately 90% of cases, Helicobacter pylori (H. pylori) infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 50%-90% of cases. In H. pylori-dependent cases, microbe-generated immune responses, including interaction between B and T cells involving CD40 and CD40L co-stimulatory molecules, are considered to induce the development of MALT lymphoma. In H. pylori-independent cases, activation of the nuclear factor-κB pathway by oncogenic products of specific chromosomal translocations such as t(11;18)/API2-MALT1, or inactivation of tumor necrosis factor alpha-induced protein 3 (A20) are considered to contribute to the lymphomagenesis. Recently, a large-scale Japanese multicenter study confirmed that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent. Treatment modalities for patients not responding to H. pylori eradication include a "watch and wait" strategy, radiotherapy, chemotherapy, rituximab immunotherapy, and a combination of these. Because of the indolent behavior of MALT lymphoma, second-line treatment should be tailored in consideration of the clinical stage and extent of the disease in each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.